PL3655395T3 - Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu - Google Patents

Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu

Info

Publication number
PL3655395T3
PL3655395T3 PL18785785T PL18785785T PL3655395T3 PL 3655395 T3 PL3655395 T3 PL 3655395T3 PL 18785785 T PL18785785 T PL 18785785T PL 18785785 T PL18785785 T PL 18785785T PL 3655395 T3 PL3655395 T3 PL 3655395T3
Authority
PL
Poland
Prior art keywords
tert
butylpyrazolo
oxopyrrolidin
triazin
ylamino
Prior art date
Application number
PL18785785T
Other languages
English (en)
Inventor
Burcu Selin AYTAR
Alina BOROVIKA
Collin Chan
Joerg Deerberg
Nathan R. DOMAGALSKI
Martin D. Eastgate
Yu Fan
Michael David Bengt FENSTER
Robert V. FOREST
Francisco GONZALEZ-BOBES
Rebecca A. GREEN
Matthew R. Hickey
Nathaniel David KOPP
Thomas E. LA CRUZ
Kathleen LAUSER
Hong Geun Lee
David K. Leahy
Helen Y. LUO
Thomas M. Razler
Scott A. Savage
Chris SFOUGGATAKIS
Maxime C.D. SOUMEILLANT
Serge ZARETSKY
Bin Zheng
Ye Zhu
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3655395T3 publication Critical patent/PL3655395T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
PL18785785T 2017-07-20 2018-07-19 Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu PL3655395T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534908P 2017-07-20 2017-07-20
PCT/US2018/042797 WO2019018592A2 (en) 2017-07-20 2018-07-19 PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide
EP18785785.9A EP3655395B1 (en) 2017-07-20 2018-07-19 Process for the preparation of n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide

Publications (1)

Publication Number Publication Date
PL3655395T3 true PL3655395T3 (pl) 2022-03-07

Family

ID=63834628

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18785785T PL3655395T3 (pl) 2017-07-20 2018-07-19 Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu

Country Status (23)

Country Link
US (2) US11254679B2 (pl)
EP (1) EP3655395B1 (pl)
JP (1) JP2020527576A (pl)
KR (1) KR20200031656A (pl)
CN (1) CN110933946A (pl)
AU (1) AU2018304290B2 (pl)
BR (1) BR112020000418A2 (pl)
CA (1) CA3070423A1 (pl)
CY (1) CY1125023T1 (pl)
DK (1) DK3655395T3 (pl)
EA (1) EA202090346A1 (pl)
ES (1) ES2907640T3 (pl)
HR (1) HRP20220264T8 (pl)
HU (1) HUE058049T2 (pl)
IL (2) IL293088A (pl)
LT (1) LT3655395T (pl)
PL (1) PL3655395T3 (pl)
PT (1) PT3655395T (pl)
RS (1) RS62941B1 (pl)
SG (1) SG11202000441QA (pl)
SI (1) SI3655395T1 (pl)
SM (1) SMT202200088T1 (pl)
WO (1) WO2019018592A2 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006823XA (en) * 2018-01-22 2020-08-28 Bristol Myers Squibb Co Compositions and methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1646633B1 (en) * 2003-05-30 2009-04-15 Choongwae Pharma Corporation Beta-strand mimetics
US7671062B2 (en) * 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
CN100593536C (zh) * 2007-01-09 2010-03-10 吉尔生化(上海)有限公司 一种n-芴甲氧羰基-n-三苯甲基-d-谷氨酰胺的合成法
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
TWI852183B (zh) * 2011-12-28 2024-08-11 日商中外製藥股份有限公司 胜肽化合物之環化方法

Also Published As

Publication number Publication date
BR112020000418A2 (pt) 2020-07-14
HUE058049T2 (hu) 2022-06-28
HRP20220264T8 (hr) 2022-05-27
CA3070423A1 (en) 2019-01-24
IL272034A (en) 2020-03-31
EA202090346A1 (ru) 2020-08-18
KR20200031656A (ko) 2020-03-24
US20220177482A1 (en) 2022-06-09
EP3655395B1 (en) 2021-12-01
EP3655395A2 (en) 2020-05-27
HRP20220264T1 (hr) 2022-05-13
DK3655395T3 (da) 2022-03-07
WO2019018592A3 (en) 2019-02-28
JP2020527576A (ja) 2020-09-10
AU2018304290A8 (en) 2020-04-02
PT3655395T (pt) 2022-02-22
IL272034B (en) 2022-06-01
AU2018304290A1 (en) 2020-03-05
RS62941B1 (sr) 2022-03-31
SG11202000441QA (en) 2020-02-27
LT3655395T (lt) 2022-03-10
ES2907640T3 (es) 2022-04-25
AU2018304290B2 (en) 2022-11-17
WO2019018592A2 (en) 2019-01-24
CY1125023T1 (el) 2023-03-24
US11254679B2 (en) 2022-02-22
SMT202200088T1 (it) 2022-03-21
US20200223852A1 (en) 2020-07-16
IL293088A (en) 2022-07-01
SI3655395T1 (sl) 2022-04-29
CN110933946A (zh) 2020-03-27

Similar Documents

Publication Publication Date Title
PT3458456T (pt) Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
IL262003A (en) Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
HK1244483A1 (zh) (s)-n-(5 - ((r)-2-(2,5-二氟苯基)吡咯烷-1-基) - 吡唑并[1,5-a ]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐
HUE049989T2 (hu) (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-N-(piridin-2-il)benzamid szilárd alakjai és készítményei
SI2885266T1 (sl) Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
EP4025235C0 (en) OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEIITIS
HUE072069T2 (hu) 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
HRP20220264T8 (hr) Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamida
HK40032669A (en) Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
HK40023888A (en) 11,13-modified saxitoxins for the treatment of pain
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin
HK1242618A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine